Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Walters, Thomas
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery	Completed	2	91	US	VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle	VivaVision Biotech, Inc	Inflammation	05/24	05/24
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension	Active, not recruiting	2	126	US	T4090 0.2%, T4090 0.3%, Rhopressa®	Laboratoires Thea	Glaucoma, Ocular Hypertension	05/25	05/25
Jasek, Cindy
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery	Completed	2	91	US	VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle	VivaVision Biotech, Inc	Inflammation	05/24	05/24